Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Induction Cetuximab (IM-C225), Gemcitabine and Oxaliplatin, Followed by Radiotherapy With Concurrent Capecitabine, and Cetuximab, Followed by Maintenance Cetuximab and Gemcitabine for Patients With Locally Advanced Pancreatic Cancer.

Next Previous
Trial Profile

Phase II Trial of Induction Cetuximab (IM-C225), Gemcitabine and Oxaliplatin, Followed by Radiotherapy With Concurrent Capecitabine, and Cetuximab, Followed by Maintenance Cetuximab and Gemcitabine for Patients With Locally Advanced Pancreatic Cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Capecitabine; Gemcitabine; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Therapeutic Use

Most Recent Events

  • 21 Mar 2013 Primary endpoint added as reported by ClinicalTrials.gov.
  • 13 Apr 2011 Planned End Date changed from 1 Sep 2011 to 1 Sep 2012, according to ClinicalTrials.gov.
  • 11 Aug 2010 Planned end date changed from 1 Sep 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top